Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Similar articles for PubMed (Select 23431996)

1.

Effect of a single intraoperative high-dose ATG-Fresenius on delayed graft function in donation after cardiac-death donor renal allograft recipients: a randomized study.

van den Hoogen MW, Kho MM, Abrahams AC, van Zuilen AD, Sanders JS, van Dijk M, Hilbrands LB, Weimar W, Hoitsma AJ.

Exp Clin Transplant. 2013 Apr;11(2):134-41. doi: 10.6002/ect.2012.0220. Epub 2013 Feb 22.

2.

Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.

Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.

Transpl Immunol. 2008 Jan;18(3):281-5. Epub 2007 Aug 28.

PMID:
18047938
4.

Early allograft biopsies performed during delayed graft function may not be necessary under thymoglobulin induction.

Ortiz J, Parsikia A, Mumtaz K, Khanmoradi K, Balasubramanian M, Feyssa E, Campos S, Zaki R, Chewaproug D.

Exp Clin Transplant. 2012 Jun;10(3):232-8.

5.

Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.

Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, Moreso F, Fernandez A, Torras J, Riera L, Castelao AM, Alsina J.

Nephrol Dial Transplant. 1998 Oct;13(10):2601-4.

7.

Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.

Guba M, Rentsch M, Wimmer CD, Uemueksuez A, Illner WD, Schönermarck U, Land WG, Jauch KW, Arbogast H.

Transpl Int. 2008 Jul;21(7):637-45. doi: 10.1111/j.1432-2277.2008.00658.x. Epub 2008 Feb 16.

PMID:
18282242
8.
9.

One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.

Wang D, Chen JH, Wu WZ, Yang SL, Wu GJ, Wang H, Tan JM.

Transplant Proc. 2007 Jan-Feb;39(1):69-72.

PMID:
17275476
10.

Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.

Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.

Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.

PMID:
18773960
11.

Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.

Cantarovich D, Rostaing L, Kamar N, Saint-Hillier Y, Ducloux D, Mourad G, Garrigue V, Wolf P, Ellero B, Cassuto E, Albano L, Soulillou JP; FRANCIA Study Trial Investigators Group.

Transpl Int. 2010 Mar 1;23(3):313-24. doi: 10.1111/j.1432-2277.2009.00971.x. Epub 2009 Oct 19.

PMID:
19843296
12.

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.

Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M.

Transplantation. 2003 Mar 27;75(6):844-51.

PMID:
12660513
13.

Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.

Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.

Transpl Int. 2003 Nov;16(11):820-7. Epub 2003 Jul 22.

PMID:
12879230
14.
15.

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.

Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.

Transplantation. 2005 Aug 27;80(4):457-65.

PMID:
16123718
16.
17.

Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.

Clin J Am Soc Nephrol. 2012 Mar;7(3):504-12. doi: 10.2215/CJN.06940711. Epub 2012 Jan 26.

18.

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.

Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.

Transplantation. 2001 Dec 27;72(12):1915-9.

PMID:
11773888
19.

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.

Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J.

Clin Transplant. 2008 Mar-Apr;22(2):200-10. doi: 10.1111/j.1399-0012.2007.00774.x.

PMID:
18339140
20.

Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation.

Ciancio G, Gaynor JJ, Roth D, Kupin W, Hanson L, Tueros L, Zarak A, Ruiz P, Burke GW 3rd.

Transplant Proc. 2010 Nov;42(9):3503-6. doi: 10.1016/j.transproceed.2010.08.045.

PMID:
21094804
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk